Kalaris Therapeutics (NASDAQ:KLRS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Kalaris Therapeutics (NASDAQ:KLRS) from a sell rating to a hold rating in a research note issued to investors on Saturday.

A number of other brokerages have also issued reports on KLRS. Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday, December 15th. Raymond James Financial initiated coverage on shares of Kalaris Therapeutics in a research note on Tuesday, September 2nd. They set a “strong-buy” rating on the stock. Finally, Citizens Jmp initiated coverage on shares of Kalaris Therapeutics in a report on Monday, November 3rd. They set a “market outperform” rating and a $20.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Kalaris Therapeutics has an average rating of “Moderate Buy” and an average price target of $11.50.

Kalaris Therapeutics Stock Up 10.2%

KLRS opened at $10.06 on Friday. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $12.90. The business has a fifty day simple moving average of $6.10 and a 200-day simple moving average of $4.40. The firm has a market cap of $188.12 million, a P/E ratio of -2.67 and a beta of -0.04.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.02.

Institutional Trading of Kalaris Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Johnson Financial Group Inc. acquired a new position in shares of Kalaris Therapeutics during the 3rd quarter worth about $58,000. Bridgeway Capital Management LLC purchased a new stake in Kalaris Therapeutics during the third quarter worth approximately $130,000. XTX Topco Ltd purchased a new stake in Kalaris Therapeutics during the second quarter worth approximately $65,000. Belpointe Asset Management LLC acquired a new position in Kalaris Therapeutics in the third quarter valued at approximately $231,000. Finally, Fortis Capital Advisors LLC purchased a new position in Kalaris Therapeutics in the third quarter valued at approximately $231,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.